Table 1.
Characteristics of the included randomized trials in the meta-analysis.
| Study | Year | Country | Phase | Group | Type of combination | No. of evaluable patients | Medianage(years) | No. of EGFR mutation | Adenocarcinoma(%) | Efficacy | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19 del | L858R | ORR | PFS | OS | |||||||||
| CALGB 30406 | 2012 | USA | II | Paclitaxel plus carboplatin+ E | Concurrent | 33 | 60 | 16 | 17 | 84 | 73% | 17.2 m | 38.1 m |
| E | 33 | 58 | 23 | 10 | 88 | 70% | 14.1 m | 31.3 m | |||||
| Yang et al. (15) | 2014 | East Asia | III | Pemetrexed plus cisplatin +G | Sequential | 26 | 59 | 14 | 10 | 97 | 65.4% | 12.9 m | 32.4 m |
| G | 24 | 59 | 11 | 13 | 97 | 70.8% | 16.6 m | 45.7 m | |||||
| An et al. (8) | 2016 | China | II | Pemetrexed +G | Intercalated | 45 | 65.7 | 16 | 29 | 100 | 80.0% | 18.0 m | 34.0 m |
| G | 45 | 66.9 | 17 | 28 | 100 | 73.3% | 14.0 m | 32.0 m | |||||
| Cheng et al. (16) | 2016 | East Asia | II | Pemetrexed +G | Concurrent | 126 | 62 | 65 | 52 | NA | 80.2% | 15.8 m | 43.4 m |
| G | 65 | 62 | 40 | 23 | NA | 73.8% | 10.9 m | 36.8 m | |||||
| Han et al. (17) | 2017 | China | II | Pemetrexed plus carboplatin +G | Intercalated | 40 | NA | 21 | 19 | 100 | 82.5% | 17.5 m | 32.6 m |
| G | 41 | NA | 21 | 20 | 100 | 65.9% | 11.9 m | 25.8 m | |||||
| NEJ009 | 2019 | Japan | III | Pemetrexed plus carboplatin +G | Concurrent | 170 | 64.8 | 93 | 69 | 98.8 | 84% | 20.9 m | 50.9 m |
| G | 172 | 64.0 | 95 | 67 | 98.8 | 67% | 11.9 m | 38.8 m | |||||
| Noronha | 2019 | India | III | Pemetrexed plus carboplatin +G | Concurrent | 174 | 54 | 107 | 60 | 98 | 75.3% | 16.0 m | NR |
| G | 176 | 56 | 109 | 60 | 97 | 62.5% | 8.0 m | 17.0 m | |||||
| Xu et al. (18) | 2019 | China | II | Pemetrexed plus carboplatin +I | Intercalated | 90 | 58.6 | 51 | 38 | 100 | 77.8% | 16.0 m | 36.0 m |
| I | 89 | 61.0 | 52 | 37 | 100 | 64.0% | 10.0 m | 34.0 m | |||||
E, erlotinib; G, Gefitinib; I, icotinib; ORR, objective response rate; PFS, progression free survival; OS, over survival; NA, not available; NR, not reach; EGFR, epidermal growth factor receptor; m, months.